PAZUFLOXACIN MESILATE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C16H15FN2O4.CH4O3S
Molecular Weight	414.405
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CS(O)(=O)=O.C[C@H]1COC2=C(C(F)=CC3=C2N1C=C(C(O)=O)C3=O)C4(N)CC4

InChI

InChIKey=UDHGFPATQWQARM-FJXQXJEOSA-N

InChI=1S/C16H15FN2O4.CH4O3S/c1-7-6-23-14-11(16(18)2-3-16)10(17)4-8-12(14)19(7)5-9(13(8)20)15(21)22;1-5(2,3)4/h4-5,7H,2-3,6,18H2,1H3,(H,21,22);1H3,(H,2,3,4)/t7-;/m0./s1

HIDE SMILES / InChI

Description

Pazufloxacin is a fused tricyclic quinolone derivative that has a broad spectrum of anti-bacterial activity. Pazufloxacin inhibits bot DNA gyrase and topoisomerase IV and has shown in vitro activity against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Klebsiella, Enterobacter, Hafnia, Citrobacter, Proteus, Providencia, Serratia, Shigella, Salmonella, Aeromonas and Yersinia. The drug is used for the treatment of infectious diseases such as abdominal infections, genital infections, urinary tract infections, respiratory tract infections, etc.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial DNA gyrase	Inhibitor
Topoisomerase IV	Inhibitor

Conditions

Condition	Modality	Highest Phase	Product
Abdominal infections	Curative	Approved	PASIL
Genital infections	Curative	Approved	PASIL
Urinary tract infections	Curative	Approved	PASIL
Respiratory tract infections	Curative	Approved	PASIL
Secondary infections after injuries, burns and post-operative	Curative	Approved	PASIL

C_max

Value	Dose	Analyte	Population
8.99 μg/mL	300 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
11 μg/mL	500 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
18.45 μg/mL	1000 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
11 μg/mL	500 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
13 μg/mL	500 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
11.2 μg/mL	500 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
11.6 μg/mL	500 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
12.3 μg/mL	500 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
10.9 μg/mL	500 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
18.45 μg/mL	1000 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
23.38 μg/mL	1000 mg 2 times / day steady-state, intravenous	PAZUFLOXACIN serum	Homo sapiens
18.3 μg/mL	500 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
11 μg/mL	500 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
25.74 μg/mL	1000 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
18.45 μg/mL	1000 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
25.74 μg/mL	1000 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
25.44 μg/mL	1000 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
13 μg/mL	1000 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
10.47 μg/mL	300 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens

AUC

Value	Dose	Analyte	Population
13.3 μg × h/mL	300 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
21.7 μg × h/mL	500 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
59.42 μg × h/mL	1000 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
21.7 μg × h/mL	500 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
57.1 μg × h/mL	1000 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
57.81 μg × h/mL	1000 mg 2 times / day steady-state, intravenous	PAZUFLOXACIN serum	Homo sapiens
37.2 μg × h/mL	500 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
21.7 μg × h/mL	500 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
73.18 μg × h/mL	1000 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
59.42 μg × h/mL	1000 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
69.21 μg × h/mL	1000 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
71.33 μg × h/mL	1000 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
241 μg × h/mL	1000 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
421 μg × h/mL	300 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens

T_1/2

Value	Dose	Analyte	Population
1.65 h	300 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
1.88 h	500 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
3 h	1000 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
1.88 h	500 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
3 h	1000 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
2.9 h	1000 mg 2 times / day steady-state, intravenous	PAZUFLOXACIN serum	Homo sapiens
2.04 h	500 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
1.88 h	500 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
3 h	1000 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
3 h	1000 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens
3 h	1000 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
3.6 h	1000 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
21.2 h	1000 mg 2 times / day multiple, intravenous	PAZUFLOXACIN serum	Homo sapiens
31.9 h	300 mg single, intravenous	PAZUFLOXACIN serum	Homo sapiens

F_unbound

Value	Dose	Co-administered	Analyte	Population
69.3%			PAZUFLOXACIN serum	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
1000 mg single, intravenous Highest studied dose	healthy, ADULT
2000 mg single, intravenous Highest studied dose	healthy, ADULT	Disc. AE: Erythema...
1000 mg 2 times / day multiple, intravenous Recommended\|Studied dose	healthy, ADULT	Disc. AE: Injection site irritation, Hives... Other AEs: Erythema, Erythema...
1000 mg 2 times / day multiple, intravenous Recommended\|Studied dose	unhealthy, ADULT	Disc. AE: Injection site erythema, Vomiting... Other AEs: Injection site swelling...

Showing 1 to 4 of 4 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Erythema	12.5% Disc. AE	2000 mg single, intravenous Highest studied dose	healthy, ADULT
Erythema		1000 mg 2 times / day multiple, intravenous Recommended\|Studied dose	healthy, ADULT
Erythema	12.5%	1000 mg 2 times / day multiple, intravenous Recommended\|Studied dose	healthy, ADULT
Hives	Disc. AE	1000 mg 2 times / day multiple, intravenous Recommended\|Studied dose	healthy, ADULT
Injection site irritation	Disc. AE	1000 mg 2 times / day multiple, intravenous Recommended\|Studied dose	healthy, ADULT

Showing 1 to 5 of 20 entries

Previous1 2 3 4Next

PubMed

Show entries

Title	Date	PubMed
[Drug interactions between nonsteroidal anti-inflammatory drug and pazufloxacin mesilate, a new quinolone antibacterial agent for intravenous use: convulsions in mice after intravenous or intracerebroventricular administration].	2002 Jun	12199111

Showing 1 to 1 of 1 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

The usually recommended dose of Pazufloxacin Injections in most infections is 500 mg twice a day administered as an I.V. infusion over 30-60 minutes. Depending on age, symptoms and severity of infection, the dose of the drug may be reduced to 300 mg twice a day.

Route of Administration: Intravenous

In Vitro Use Guide

Pazufloxacin has good antibacterial activity against variety of clinical isolates. The MICs at which 90% of the isolates were inhibited (MIC90s) of pazufloxacin were 0.2 to 0.39 ug/ml for Staphylococcus aureus and Staphylococcus epidermidis, including methicillin-resistant strains.5 Pazufloxacin has similar or 2-fold greater activity than other quinolones, against the following Enterobacteriaceae (MIC90 ≤ 0.25 ug/ml): Escherichia coli, Klebsiella, Enterobacter, Hafnia, Citrobacter, Proteus, Providencia, Serratia, Shigella, Salmonella, Aeromonas and Yersinia. Against P. aeruginosa, pazufloxacin shows more potent activity than tosufloxacin, norfloxacin and ofloxacin. Against clinical isolates of methicillin-resistant Staphylococcus aureus and P. aeruginosa, pazufloxacin has an MIC90 of 0.39 ug/ml and an MIC90 of 0.78 ug/ml respectively. MIC90 for clinical isolates of H. influenzae is ≤ 0.013 ug/l.

Show entries

Name

Type

Language

PAZUFLOXACIN MESILATE

Common Name

English

PAZUFLOXACIN METHANESULFONATE

Common Name

English

PAZUFLOXACIN MESYLATE

Common Name

English

(-)-(3S)-10-(1-AMINOCYCLOPROPYL)-9-FLUORO-2,3-DIHYDRO-3-METHYL-7-OXO-7H-PYRIDO(1,2,3-DE)-1,4-BENZOXAZINE-6-CARBOXYLIC ACID METHANESULFONATE

Systematic Name

English

Pazufloxacin mesilate [WHO-DD]

Common Name

English

Showing 1 to 5 of 10 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

EVMPD

SUB16450MIG

PRIMARY

NSC

759831

PRIMARY

PUBCHEM

6918232

PRIMARY

CAS

163680-77-1

PRIMARY

MERCK INDEX

m8431

PRIMARY

Merck Index

Showing 1 to 5 of 9 entries

Previous1 2Next

ACTIVE MOIETY


					4CZ1R38NDI

PAZUFLOXACIN

SUBSTANCE RECORD


					2XI226J1HS

PAZUFLOXACIN MESILATE

SMILES

InChI

Originator

Approval Year

Targets

Conditions

Cmax

AUC

T1/2

Funbound

Doses

AEs

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound